This study will compare the relative bioavailability (rate and extent of absorption) of 300
mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of
OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a
single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting
conditions.